Monocyte chemoattractant protein-1 and the kidney
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Recently, initial studies have been carried out in patients using monocyte chemoattractant protein-1 (MCP-1) inhibitors. This review summarizes the known function of MCP-1 in regulating monocytes during inflammation and its role in inflammatory disease of the kidney. RECENT FINDINGS: MCP-1 is one of the first chemokines described and plays an important role in renal inflammatory disease. The function of MCP-1 has been investigated and analyzed in both animal models of renal disease and renal patients. MCP-1 mediates firstly the release of monocytes from the bone marrow, and then generates a gradient in the endothelial glycocalyx to direct monocytes to sites of inflammation, thereby alleviating the migration of blood leukocytes into the inflamed tissue. In addition, MCP-1 has direct signaling effects in monocytes and influences migration, proliferation, and differentiation of leukocytes. Blockade of MCP-1 in several models of renal disease has ameliorated the disease, suggesting that inhibition of MCP-1 is a promising and valid strategy to treat patients with renal inflammatory disease. SUMMARY: Understanding the role of MCP-1 in monocyte homeostasis and the implications of MCP-1 inhibition in renal disease will help in designing better diagnostic and therapeutic strategies in patients with inflammatory renal disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation
Italiani, P., & Boraschi, D. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00514 · Cited by 2,067
Distinct macrophage phenotypes contribute to kidney injury and repair
Lee, S., Huen, S., Nishio, H., Nishio, S., Lee, H. K., Choi, B.-S., Ruhrberg, C., & Cantley, L. G. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009060615 · Cited by 906 · cited 1×
“MCP-1 inhibition and reduction of monocyte/macrophage infiltration seem to be promising targets for future treatment of diabetic nephropathy [90].”
BackgroundPathogenesis of diabetic nephropathy
Cao, Z., & Cooper, M. E. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00131.x · Cited by 219
Cited by
Macrophages: versatile players in renal inflammation and fibrosis
Tang, P. M.-K., Nikolic-Paterson, D. J., & Lan, H.-Y. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0110-2 · Cited by 1,033
Wu, H., Kirita, Y., Donnelly, E. L., & Humphreys, B. D. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018090912 · Cited by 752
Role of MCP-1 as an inflammatory biomarker in nephropathy
Liu, Y., Xu, K., Xiang, Y., Ma, B., Li, H., Li, Y., Shi, Y., Li, S., & Bai, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303076 · Cited by 93
Monocytes and macrophages as protagonists in vascular complications of diabetes
Kanter, J. E., Hsu, C.-C., & Bornfeldt, K. E. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00010 · Cited by 76
Rabbani, N., Xue, M., Weickert, M. O., & Thornalley, P. J. (2021) · Nutrients · doi:10.3390/nu13072374 · Cited by 74
Metadata
- Authors
- Haller, H., Bertram, A., Nadrowitz, F., & Menne, J.
- Venue
- Current Opinion in Nephrology and Hypertension
- Published
- 2016-01
- Volume
- 25
- Issue
- 1
- Pages
- 42-49
- ISSN
- 1062-4821 (ISSN-L)
- OpenAlex
- W2419906038
- Cited by
- 184
- References
- 3
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Monocyte chemoattractant protein-1 and the kidney. https://app.cochat.ai/papers/10.1097/mnh.0000000000000186
- The paper
- Haller, H., Bertram, A., Nadrowitz, F., & Menne, J. (2016). Monocyte chemoattractant protein-1 and the kidney. Current Opinion in Nephrology and Hypertension. https://doi.org/10.1097/mnh.0000000000000186
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.